Appln. No.: 10/598,533

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A method for the prevention or treatment of overactive bladder accompanied with neurogenic disorders, which comprises administering an effective amount of an indoline derivative represented by a formula:

wherein in the formula, R represents a saturated or unsaturated aliphatic acyl group which may have as a substituent a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group, an aryl group or one or more halogen atoms; a hydroxy lower alkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group which has as a substituent a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl-substituted lower alkoxycarbonyl group, a carbamoyl group, a mono or di(lower alkyl)-substituted carbamoyl group or a cyano group; an aromatic acyl group which may have as a substituent one or more halogen atoms; a furoyl group or a pyridylcarbonyl group; R¹ represents a cyano group or a carbamoyl group; R² represents a lower alkyl group which may have as a substituent a cyano group, an aryl group or one or more halogen atoms; or a pharmaceutically acceptable salt thereof.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q96716

Appln. No.: 10/598,533

2. (currently amended): A method for the prevention or treatment as claimed in claim 1, which comprises administering an effective amount of (-)-1-(3-hydroxypropyl)-5-((2R)-2-{[2-({2-[(2,2,2-trifluoro-ethyl)oxy]phenyl}oxy)ethyl]amino}propyl)-2,3-dihydro-1H-indol-7-carboxamide or a pharmaceutically acceptable salt thereof.

- 3. (currently amended): A method for the prevention or treatment as claimed in claim 1, wherein the neurogenic disorder is cerebral infarction, Parkinson's disease, spinal cord involvement, peripheral neurogenic disorder or multiple sclerosis.
- 4. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 1, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.
- 5. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 4 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.
- 6. (currently amended): A method for the prevention or treatment as claimed in claim 2, wherein the neurogenic disorder is cerebral infarction, Parkinson's disease, spinal cord involvement, peripheral neurogenic disorder or multiple sclerosis.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q96716

Appln. No.: 10/598,533

7. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 2, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.

- 8. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 3, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.
- 9. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 6, which comprises administering in combination with one or more other agents used for overactive bladder accompanied with neurogenic disorder.
- 10. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 7 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.
- 11. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 8 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

AMENDMENT UNDER 37 C.F.R. § 1.111

Appln. No.: 10/598,533

12. (withdrawn-currently amended): A method for the prevention or treatment as claimed in claim 9 wherein the other agent used for overactive bladder accompanied with neurogenic disorder is an agent selected from an anticholinergic drug, an anti-anxiety drug, a cholinergic drug, a cholinesterase inhibitor, an antispasmodic drug, an anti-inflammatory drug or an antimicrobial drug.

Attorney Docket No.: Q96716